The Scale-Up at a Glance

dsm-firmenich is preparing to move Protopia, its single-cell protein platform, from pilot to industrial scale. The company has produced trial batches in a 15,000-liter fermenter and plans a 120,000-liter fermentation run later this year, followed by a move into a larger dedicated facility — most likely in Eastern Europe, with access to both bioethanol and beet sugar — targeted for 2027. That facility is expected to produce roughly 2,000 to 10,000 tons of Protopia annually.

Single-cell protein — grown by fermenting microbes such as yeast, bacteria or fungi and harvesting the whole biomass — has drawn sustained investor and industry interest as a scalable route to protein production. But the field has a well-documented problem: strong lab-scale results rarely survive the jump to industrial economics. dsm-firmenich, which brings decades of large-scale biomanufacturing experience from its nutrition and enzymes businesses, argues it has closed that gap.

Built in Reverse: Cost First, Then Biology

Rather than starting from a promising microbe and hoping the economics would follow, dsm-firmenich says it worked backward from the cost of goods it needed to hit. Karim Kurmaly, the company's director of single-cell protein, describes an engineering process focused on productivity and versatility from the outset, rather than one built around a single fixed feedstock.

The company has also tested continuous fermentation but settled on a semi-continuous process, arguing that contamination risk in a fully continuous system creates outsized losses at industrial volumes — a cost-of-failure calculation as much as a technical one.

A Regulatory Path Already Cleared

Torula yeast — the species behind Protopia — has a long history of approved food use across multiple markets, including the EU. That gives dsm-firmenich a meaningful head start: Protopia can already be marketed in the US and EU without a new FDA GRAS notice or EU novel food authorization, since the underlying organism is not novel. What is new is a strain and fermentation process optimized to deliver a neutral-tasting, roughly 70%-protein ingredient at inclusion levels high enough to function as a primary protein source, rather than a minor additive. The company is separately reviewing regulatory pathways in markets including India and Brazil, where labeling is expected to read along the lines of "yeast protein" or "fermented yeast protein."

Competing With Fishmeal and Whey on Price, Not Just Sustainability

dsm-firmenich is positioning Protopia less as an environmental alternative and more as a direct commercial substitute — sized to compete on cost against two proteins currently under price pressure. High-quality fishmeal has traded near €3,000 per ton, with prices this year further strained by El Niño-related disruption to Peru's anchovy fishery, a key global fishmeal source. Whey protein, meanwhile, has become significantly more expensive and harder to source in some markets. dsm-firmenich says early aquaculture trials show Protopia performing as a one-to-one fishmeal replacement, while in pet food, palatability trials against competing proteins have also been favorable.

For human food, Protopia is supplied as a fine, off-white powder with a mild savory note, positioned for applications from snacks and meat alternatives to smoothies and dairy-free beverages, where dsm-firmenich argues it avoids the off-notes and grittiness associated with many plant proteins.

India: The Largest Strategic Opportunity

The most consequential market for Protopia may not be Europe. India has expanded ethanol production capacity rapidly to meet government biofuel-blending mandates, but adoption has lagged targets, leaving producers with significant underused capacity. That surplus, paired with India's structural protein deficit — the country produces relatively little whey because most of its dairy output goes into paneer — creates conditions for a large licensing opportunity, according to Raman "Chandru" Chandrasekar, managing director of UK-based Sustein Ltd, which advises on sustainable protein and bioeconomy projects.

Chandrasekar points to India's ethanol industry, which he says represents roughly $5 billion of invested capacity built for around 20 billion liters of output, much of it now underused as blending targets move more slowly than planned. A single Protopia module consuming 100,000 liters of ethanol per day could produce an estimated 16,000 tons of the protein annually — output that could be directed toward fortifying mass-market staples such as noodles, bread and snacks, as well as premium beverage applications already emerging through outlets such as Starbucks in India.

Licensing, Not Factories, Is the Growth Model

dsm-firmenich says it does not intend to build and operate dozens of Protopia plants itself. Instead, the company plans to license its strain, fermentation process and application know-how to local production partners — described internally as the "software" — while those partners provide the physical plant, typically co-located with existing ethanol or sugar operations to reuse feedstock, utilities and effluent infrastructure. Licensees would pay a royalty, with dsm-firmenich supporting both technical scale-up and offtake negotiations with food, feed and aquaculture buyers. The company says it is currently pursuing licensing discussions in three countries, backed by an intellectual property portfolio of more than 18 patents spanning the strain itself, process technology and downstream applications.

Relevance for Saudi Arabia and the MENA Region

For Saudi Arabia and the wider Gulf, which import the large majority of their animal feed protein and remain exposed to fishmeal and whey price volatility, a feedstock-flexible protein platform is directly relevant to food security planning under Vision 2030. The same licensing structure dsm-firmenich is pursuing in India — pairing a protein-scarce, feedstock-rich market with a technology partner rather than a capital-intensive standalone plant — is a model regional aquaculture, animal feed and food manufacturing players will likely watch closely, particularly given the Kingdom's growing investment in domestic aquaculture and its ambitions to reduce feed-protein import dependency.

The regulatory logic also matters regionally: a protein that can reach food and feed markets without a lengthy novel-ingredient approval process is a materially faster route to market than most fermentation-derived proteins currently being evaluated by MENA food and feed companies.

Editorial View

Single-cell protein has spent years accumulating pilot-scale proof points without a clear industrial cost story. dsm-firmenich's pitch is narrower and more commercial than most in the category: not a novel-food breakthrough, but an established, already-approved organism engineered for productivity and feedstock flexibility, priced deliberately to compete with fishmeal and whey rather than merely position itself as their sustainable alternative. The India opportunity, in particular, illustrates a pattern likely to recur elsewhere, including in parts of MENA: protein scarcity paired with underused industrial feedstock capacity is exactly the gap this kind of licensing model is designed to fill.